Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports

  • Authors:
    • Hisashi Takeuchi
    • Naoto Tokuyama
    • Isao Kuroda
    • Teiichiro Aoyagi
  • View Affiliations

  • Published online on: February 20, 2018     https://doi.org/10.3892/etm.2018.5882
  • Pages: 3976-3980
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Molecular targeted therapies have markedly improved the prognosis of metastatic renal cell carcinoma (RCC) and patients are able to receive specific treatments depending on their condition. The cases of two patients who presented with large RCC with very different statuses were examined in the current study. One of the patients was elderly with numerous comorbidities, and the other was young and had Case 1 was an elderly female with various comorbidities including a history of cerebral infarction and impaired eyesight. A 7 cm solid mass in the left kidney, pulmonary metastases and a shrunken right kidney were identified. Conservative treatment was selected and the patient underwent treatment with oral sorafenib for 5 years without experiencing disease progression. Case 2 was a middle‑aged male in a good general condition who had a 19 cm left renal mass and multiple metastases. Due to the tumor size, the patient was initially treated with oral pazopanib to reduce the renal tumor volume and was able to undergo left radical nephrectomy after 6 months. Molecular targeted therapies were thus used to treat these patients taking into account each patient's life stage; case 1 was treated without surgery for six years and case 2 received treatment as a neoadjuvant.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takeuchi H, Tokuyama N, Kuroda I and Aoyagi T: Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports. Exp Ther Med 15: 3976-3980, 2018.
APA
Takeuchi, H., Tokuyama, N., Kuroda, I., & Aoyagi, T. (2018). Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports. Experimental and Therapeutic Medicine, 15, 3976-3980. https://doi.org/10.3892/etm.2018.5882
MLA
Takeuchi, H., Tokuyama, N., Kuroda, I., Aoyagi, T."Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports". Experimental and Therapeutic Medicine 15.4 (2018): 3976-3980.
Chicago
Takeuchi, H., Tokuyama, N., Kuroda, I., Aoyagi, T."Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports". Experimental and Therapeutic Medicine 15, no. 4 (2018): 3976-3980. https://doi.org/10.3892/etm.2018.5882